Seasonal Affective Disorders Market Analysis, Size, Share, Growth, Trends, and Forecast
Seasonal Affective Disorders Market Size
Straits Research has published a comprehensive report on the Seasonal Affective Disorders Market, which provides in-depth insights into the market's current and future prospects. According to the report, the global Seasonal Affective Disorders Market size was valued at USD 753.68 million in 2023 and is projected to reach from USD 793.24 million in 2024 to USD 1,194.44 million in 2032, growing at a CAGR of 5.25% during the forecast period (2024–2032).
Request a free request sample https://straitsresearch.com/report/seasonal-affective-disorders-market/request-sample
Drivers in the Seasonal Affective Disorders Market
The increasing prevalence of seasonal affective disorders (SAD) worldwide is a significant driver of the market. The growing awareness about SAD and its treatment options is also contributing to the market's growth. Additionally, the development of new treatments and therapies, such as light therapy and cognitive-behavioral therapy, is expected to drive the market's growth.
Key Developments in the Seasonal Affective Disorders Market
The Seasonal Affective Disorders Market has witnessed several key developments in recent years. For instance, the introduction of new light therapy products, such as portable light therapy devices, has made treatment more accessible and convenient for patients. Furthermore, the growing adoption of digital therapeutics, such as mobile apps and online platforms, is expected to transform the way SAD is diagnosed and treated.
Top Key Players in the Seasonal Affective Disorders Market
The Seasonal Affective Disorders Market is highly competitive, with several key players operating in the market. Some of the top key players in the market include:
- Pfizer Inc. (U.S.)
- Lily (U.S.)
- GlaxoSmithKline (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bausch Health Companies Inc. (Canada)
- Viatris Inc. (U.S.)
- Johnson & Johnson (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Koninklije Philips N.V. (Netherlands)
- Beurer GmbH (Germany)
- Lucimed (Belgium)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Janssen Pharmaceuticals, Inc. (Belgium)
- Carex (U.S.)
- The SunBox Company (U.S.)
- Henry Schein, Inc. (U.S.)
This Report is available for purchase on @https://straitsresearch.com/buy-now/seasonal-affective-disorders-market
Segmentation Analysis of the Seasonal Affective Disorders Market
The Seasonal Affective Disorders Market can be segmented into several categories, including:
- By Type: Fall and Winter SAD, Spring and summer SAD, and Others
- By Treatment: Self-care, Phototherapy, Psychotherapy, Chronotherapy, Medications, Mind-body techniques, and Others
- By Diagnosis: Physical Exam, Laboratory Exam, Psychological Evaluation, and Others
- By End-User: Hospitals, Clinics, Household, Medical Research Centers, and Others
About Straits Research
Straits Research is a top provider of business intelligence, specializing in research, analytics, and advisory services, with a focus on delivering in-depth insights through comprehensive reports. Our team of experienced analysts and researchers provides actionable insights and recommendations to help businesses make informed decisions.
Contact Us
Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)
Address: 825 3rd Avenue, New York, NY, USA, 10022
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)
